Treatment of Venous Thromboembolism

Introduction

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a common clinical problem. If untreated or inadequately treated, there is a high risk of fatal PE¹ and recurrent venous thrombosis.^2-4 The objectives of treatment are to prevent local extension of thrombus, embolization, and recurrent thrombosis.

It is now widely accepted that VTE is a single disorder and, therefore, the treatment of venous thrombosis and PE is essentially the same. Four treatment modalities are available. Anticoagulant therapy prevents the growth of an existing thrombus or embolus, thrombolytic therapy accelerates the rate of dissolution of thrombi or emboli, caval interruption intercepts venous thrombi that break off and embolize, thereby preventing dangerous PE, and surgical therapy removes thrombi or emboli.

• References

• 1 Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 1: 1309-1312.
• 2 Hull R, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-858.
• 3 Brandjes DPM, Heijboer H, Buller HR. et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal vein thrombosis. N Engl J Med 1992; 327: 1485-1489.
• 4 Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985; i: 515-518.
• 5 Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosenbloom D, Sackett DL, Anderson C, Harrison L. et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-1114
• 6 Glimelius B, Busch C, Hook M. Binding of heparin on the surface of cultured endothelial cells. Thromb Res 1978; 12: 73-82.
• 7 Hiebert LM, Jacques LM. The observation of heparin on the endothelium after injection. Thromb Res 1976; 8: 195-204.
• 8 Lane DA. Heparin binding and neutralizing proteins. In: Lane DA, Lindahl U. eds. Heparin: Chemical and Biological Properties and Clinical Applications. Boca Raton, FL: CRC Press; 1989: 363-391.
• 9 Sobel M, McNeil PM, Carlson PL, Kermode JC, Adelman D, Conroy R, Marques D. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991; 87: 1787-1793.
• 10 DeRomeuf C, Mazurier C. Heparin binding assay of von Willebrand factor (vWF) in plasma milieu–evidence of the importance of the multimerization degree of vWF. Thromb Haemost 1993; 69: 436-440.
• 11 Young E, Prins M, Levine MN, Hirsh J. Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemost 1992; 67: 639-643.
• 12 Young E, Cosmi B, Weitz J, Hirsh J. Comparison of the nonspecific binding of unfractionated heparin and low molecular weight heparin to plasma proteins. Thromb Haemost 1993; 70: 625-630.
• 13 Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1:Heparin. Circulation 1994; 89: 1449-1468.
• 14 Chiu HM, Hirsh J, Yung WL, Regoeczi E, Gent M. Relationship between the anticoagulant and antithrombotic effects of heparin in experimental venous thrombosis. Blood 1977; 49: 171-184.
• 15 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-327.
• 16 Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104-109.
• 17 Hirsh J. Heparin. N Engl J Med 1991; 324: 1565-1574.
• 18 Siragusa S, Cosmi B, Piovellla Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 269-277.
• 19 Dolovich L, Ginsberg JS. Low molecular weight heparins in the treatment of venous thromboembolism: an updated meta-analysis. Vessels 1997; 3: 4.
• 20 The Columbus Investigators. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. N Engl J Med 1997; 337: 657-662
• 21 Simonneau G, Sors H, Charbonnier B. for the THESEE Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med 1997; 337: 663-669.
• 22 Levine MN, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334: 677-681.
• 23 Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, d’Azemar P, Buller HR. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996; 334: 682-687.
• 24 Cruikshank MK, Levine MN, Hirsh J, Roberts RS, Siguenza M. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151: 333-337.
• 25 Hull RD, Raskob GE, Rosenbloom DR, Lemaire J, Pineo GF, Baylis B, Ginsberg JS, Panju AA, Brill-Edwards P, Brant R. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152: 1589-1595.
• 26 Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a “standard care nomogram”. Ann Intern Med 1993; 119: 874-881.
• 27 Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996; 335: 1816-1828.
• 28 Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M. A randomized trial comparing the activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.
• 29 Pini M, Pattacini C, Quintavalla R. et al. Subcutaneous vs. intravenous heparin in the treatment of deep venous thrombosis–a randomized clinical trial. Thromb Haemost 1990; 64: 222-226.
• 30 Hommes DW, Bura A, Mazzolai L, Buller HR, ten Cate JW. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. Ann Intern Med 1992; 116: 279-284.
• 31 Doyle DJ, Turpie AGG, Hirsh J, Best C, Kinch D, Levine MN, Gent M. Adjusted subcutaneous heparin or continuous intravenous heparin in patients with acute deep vein thrombosis: randomized trial. Ann Intern Med 1987; 107: 441-446.
• 32 Bentley PG, Kakkar VV, Scully MF, MacGregor IR, Webb P, Chan P, Jones N. An objective study of alternative methods of heparin administration. Thomb Res 1980; 18: 177-187.
• 33 Andersson G, Fagrell B, Holmgren K, Johnsson H, Ljungberg B, Nilsson E, Wilhelmsson S, Zetterquist S. Subcutaneous administration of heparin: randomised comparison with intravenous administration of heparin to patients with deep vein thrombosis. Thromb Res 1982; 27: 631-639.
• 34 Walker MG, Shaw JW, Thomson GJL. et al. Subcutaneous calcium heparin versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective randomized trial. Br J Med 1987; 294: 1189-1192.
• 35 Wilson JR, Lampman J. Heparin therapy: a randomized prospective study. Am Heart J 1979; 97: 155-158.
• 36 Gallus A, Jackaman J, Tillet J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; ii: 1293-1296.
• 37 Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-1264.
• 38 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 70: 1-17.
• 39 Rosenberg RD, Bauer KA. The heparin-antithrombin system. A natural anticoagulant mechanism. In: Colman RW, Hirsh J, Marder VJ, Salzman EW. eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 3rd ed.. Philadelphia, PA: Lipincott; 1994: 837-860.
• 40 Weitz J. Low-molecular-weight heparins. N Engl J Med 1997; 337: 688-698.
• 41 Danielsson A, Raub E, Lindahl U, Bjork I. Role of ternary complexes in which heparin binds both antithrombin and proteinase in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261: 15667-15473.
• 42 Barzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochem Biophys Acta 1985; 845: 196-203.
• 43 Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and invitro evidence that low-molecular-weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1995; 71: 300-304.
• 44 Manson L, Rischke J, Weitz J, Young E, Hirsh J. Comparison of the effect of experimental endotoxaemia on the pharmacokinetics and Pharmacodynamics of low molecular weight heparin with unfractionated heparin. In progress.
• 45 Bara L, Billaud E, Gramond G, Kher A, Samama M. Comparative pharmacokinetics of a low-molecular-weight heparin (PK 10169) and unfractionated heparin and intravenous and subcutaneous administration. Thromb Res 1985; 30: 631-635.
• 46 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M, Kelton JG. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330-1335.
• 47 Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980; 65: 64073.
• 48 Bhandi M, Hirsh J, Weitz JI, Young E, Venner TJ, Shaughnessy SG. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 1998; 80: 413-417.
• 49 Bhandari M, Hirsh J, Weitz JI, Shaughnessy SG. The effect of heparin and low molecular-weight heparin on osteoblastogenesis in vitro. Blood (Suppl. 01) 1998; 92: 358a.
• 50 Monreal M, Lafoz E, Olive A, Del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
• 51 Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliot G, Lerner RB, Hall J, Sparling T, Brettell HR, Norton J, Carter CJ, George R, Merli G, Ward M, Mayo W, Rosenbloom D, Brant R. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982
• 52 Kanis JA. Heparin in the treatment of pulmonary thromboembolism. Thromb Diath Haemorrh 1974; 32: 519.
• 53 Tibbutt DA, Davies JA, Anderson JA, Fletcher EW, Hamill J, Holt JM, Thomas ML, Lee G, Miller GA, Sharp AA, Sutton GC. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. Br Med J 1974; 1: 343-347.
• 54 Miller GAH, Sutton GC, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in the treatment of isolated acute massive pulmonary embolism. Br Med J 1971; 2: 681.
• 55 The Urokinase Pulmonary Embolism Trial. A National Cooperative Study. Circulation 1973; 47 (Suppl) 1-100.
• 56 Miller GAH, Hall RJC, Paneth M. Pulmonary embolectomy, heparin and streptokinase: their place in the treatment of acute massive pulmonary embolism. Am Heart J 1977; 93: 568-574.
• 57 Lensing AWA, Hirsh J. Rationale and results of thrombolytic therapy for deep-vein thrombosis. Thromb Res 1992; 65.
• 58 Anderson D, Levine MN. Thrombolytic therapy for the treatment of acute pulmonary embolism. Can Med Assoc J 1992; 146: 1317.
• 59 Elliot MN, Immelman EJ, Benatar JSR, Benatar SR, Funston MR, Smith JA, Shepstone BJ, Ferguson AD, Jacobs P, Walker W, Louw JH. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal vein thrombosis: an interim report of a prospective trial. Br J Surg 1979; 66: 838-843.
• 60 Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analysis of randomized trials of streptokinase and heparin in phlebographically documented acute deep vein thrombosis. Am J Med 1984; 76: 393-398.
• 61 Rogers LQ, Lutcher DL. Streptokinase therapy for deep-vein thrombosis: a comprehensive review of the English literature. Am J Med 1990; 88: 389-395.
• 62 Ly B, Arnesen H, Eie H, Hol R. A controlled trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scan 1978; 203: 465-470.
• 63 Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473-1478.
• 64 Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980; 303: 842-845.
• 65 Sharma GVRK, Folland ED, McIntyre KM. et al. Long-term hemodynamic benefit of thrombolytic therapy in pulmonary embolic disease. J Am Coll Cardiol 1990; 15: 65A.
• 66 Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, Taveira da Silva AM, Come PC, Lee RT, Parker JA. et al. Alteplase versus heparin in acute pulmonary embolism: randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993; 341: 507-511.
• 67 Comerota AJ, Aldridge SC, Cohen G, Ball DS, Pliskin M, White JV. A strategy of aggressive regional therapy for acute iliofemoral venous thrombosis with contemporary venous thrombectomy or catheter-directed thrombolysis. J Vasc Surg 1994; 20: 244-254.
• 68 Verhaeghe R, Stockx L, Lacroix H, Vermylen J, Baert AL. Catheter-directed lysis of iliofemoral vein thrombosis with use of rt-PA. Eur Radiol 1997; 7: 996-1001.
• 69 Heymans S, Verhaege R, Stockx L, Collen D. Feasibility study of catheter-directed thrombolysis with recombinant staphylokinase in deep venous thrombosis. Thromb Haemost 1998; 79: 517-519.
• 70 Mewissen MW, Seabrook GR, Meissner MN, Haughton SH. Catheter-directed thrombolysis for symptomatic lower extremity deep vein thrombosis. Blood 1998; 92 (Suppl. 01) 501a.
• 71 Becker DM, Philbrick JR, Selby B. Inferior vena cava filters. Indications, safety, effectiveness. Arch Intern Med 1992; 152: 1985-1994.
• 72 Jones TK, Barnes RW, Greenfield L. Greenfield vena cava filter: rationale and indications. Ann Thorac Surg 1986; 42: 248.
• 73 Calligato KD, Bergen WS, Hour MJ. et al. Thromboembolic complications in patients with advanced cancer; anticoagulation versus Greenfield filter placement. Ann Vasc Surg 1991; 5: 186-189.
• 74 Decousus MN, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. N Engl J Med 1998; 338: 409-415.
• 75 Plate G, Akesson H, Einarsson E, Ohlin P, Eklof B. Long-term results of venous thrombectomy combined with temporary arteriovenous fistula. Eur J Cardiovasc Surg 1990; 4: 483-489.
• 76 Lansing AM, Davis WM. Five-year follow-up study of iliofemoral venous thrombectomy. Ann Surg 1968; 168: 620-626.
• 77 Meyer G, Tamisier D, Sors H, Stern M, Vouhe P, Makowski S, Neveux JY, Leca F, Even P. Pulmonary embolectomy: a 20-year experience at one centre. Ann Thorac Surg 1991; 41: 232-236.
• 78 ten Cate JW, Koopman MMW, Prins MH, Buller HR. Treatment of venous thromboembolism. Thromb Haemost 1995; 74: 197-203.
• 79 Jamieson SW, Auger WR, Fedullo PF, Channick RN, Kriett JM, Tarazi RY, Moser KM. Experience and results with 150 pulmonary thromboendarterectomy operations over a 29-month period. J Thorac Cardiovasc Surg 1993; 106: 116-126.
• 80 Moser KM, Daily PO, Peterson K, Dembitsky W, Vapnek JM, Shure D, Utley J, Archiblad C. Thromboendarterectomy for chronic, major-vessel thromboembolic pulmonary hypertension: immediate and long-term results in 42 patients. Ann Intern Med 1987; 107: 560-565.
• 81 Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. Circulation 1990; 81: 1735-1743.
• 82 Brady AJB, Crake T, Oakly CM. Percutaneous catheter fragmentation and distal dispersion of proximal pulmonary embolism. Lancet 1991; 338: 1186-1189.
• 83 Greenfield LJ. Catheter embolectomy. Chest 1991; 100: 593-594.
• 84 Hull RD, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-1681.
• 85 Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-997.
• 86 Ginsberg JS, Wells PS, Brill-Edwards P, Donovan D, Moffatt K, Johnston M, Stevens P, Hirsh J. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-3691.
• 87 Hull RD, Delmore T, Carter C. et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N. Engl J Med 1982; 306: 189-194.
• 88 Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Tagliaferri A, Dettori AG. Low-molecular-weight heparin in the prevention of recurrences after deep vein thrombosis. Thromb.
• 89 Holmgren K, Anderson G, Fagrell B. et al. One month versus six month therapy with oral anticoagulants after symptomatic deep vein thrombosis. Acta Med Scand 1985; 218: 279-284.89.
• 90 Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P. et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 1995; 74: 606-611.
• 91 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340 (12) 901-907.
• 92 Research Committee of the British Thoracic society. Optimum duration of anticoagulation for deep vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-876.
• 93 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKainnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340 (12) 901-907.
• 94 Shulman S, Rhedin AS, Lindmarker P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. N Engl J Med 1995; 332: 1661-1665.
• 95 Prandoni P, Lensing AWA, Buller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 192 327: 1128-1133.
• 96 Shulman S, Granqvist S, Holmstrom M. et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. N Engl J Med 1997; 336: 393-398.
• 97 Hyers TM, Agnelli G, Hull RD, Weg JG, Morris TA, Samama M, Tapson V. Anithrombotic therapy for venous thromboembolic disease. Chest 1998; 114: 561S-578S.
• 98 Kakkar VV, Flanc C, Howe CT, Clarke MB. Natural history of post-operative vein thrombosis. Lancet 1969; ii: 230-232.
• 99 Huisman MV, Buller HR, ten Cate JW, Vreeken J. Serial impedance plethysmography for suspected deep venous thrombosis in outpatients. N Engl J Med 1986; 314: 823-828.
• 100 Hull RD, Hirsh J, Carter CJ, Jay RM, Ockelford PA, Buller HR, Turpie AG, Powers P, Kinch D, Dodd PE. et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis: a randomized trial. Ann Int Med 1985; 102: 21-28.
• 101 Bergqvist D, Jaroszewski H. Deep vein thrombosis in patients with superficial thrombophlebitis of the leg. Br Med J 1986; 292: 658-659.
• 102 Skillman JJ, Kent KC, Porter DH, Dim D. Simultaneous occurrence of superficial and deep thrombophlebitis in the lower extremity. J Vasc Surg 1990; 11: 818-824.
• 103 Lutter KS, Roedersheimer R, Lohr JM, Sampson MG, Cranley JJ. Superficial thrombophlebitis diagnosed by duplex scanning. Surgery 1991; 110: 42-46.
• 104 Chengelis DL, Bendick PJ, Glover JL, Brown OW, Ranval TJ. Progression of superficial venous thrombosis to deep vein thrombosis. J Vasc Surg 1996; 24: 745-749.
• 105 Jorgensen JO, Hanel KC, Morgan AM, Hunt JM. The incidence of deep vein thrombosis in the patient with superficial thrombophlebitis of the lower limbs. J Vasc Surg 1993; 18: 70-73.
• 106 Flessa HC, Kapstrom AB, Cluck HI, Will JJ. Placental transport of heparin. Am J Obstet Gynecol 1965; 93: 570-573.
• 107 Melissari E, Parker CJ, Wilson NV, Monte G, Kanthou C, Pemberton KD, Nicolaides KS, Barrett JJ, Kakkar VV. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68: 652-565.
• 108 Hall JAB, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 21980 68: 626-656.
• 109 Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 1998; 114: 524S-530S.
• 110 Orme ML, Lewis PJ, de Swiet M, Serlin MJ, Sibeon R, Baty JD, Breckenridge AM. May mothers given warfarin breast-feed their infants?. Br Med J 1977; 1: 1564-1565.
• 111 McKenna R, Cole ER, Vasan U. Is warfarin sodium contraindicated in the lactating mother?. J Ped 1983; 103: 325-327.